/

Società

Au

Non verificato

Aurion Biotech, Inc.

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaOtticaSalute

7 comunicati stampa

Guarda tutti i comunicati

28/05/2026

Biotecnologia

Ottica

Salute

Web e Social Network

Fiere

Eventi

Aurion Biotech to Highlight Momentum Across Upcoming Eye Bank and Ophthalmology Meetings in June

Fonte

Aurion Biotech, Inc.

Emittente

1.00

0

06/05/2026

Eventi

Industria

Salute

Biologia

Biotecnologia

Medicina - Varie

Farmaceutica

Ottica

Aurion Biotech to Give Oral Presentation on Regenerative Cell Therapy for Corneal Endothelial Disease at ASGCT 2026

Fonte

Aurion Biotech, Inc.

Emittente

1.00

0

08/04/2026

Industria

Scienza

HIV, AIDS e malattie autoimmuni

Medicina - Varie

Biologia

Biotecnologia

Sanità

Farmaceutica

Salute

Ottica

Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction

Fonte

Aurion Biotech, Inc.

Emittente

1.00

0

11/03/2026

Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board

Fonte

Aurion Biotech, Inc.

Emittente

1.00

0

18/03/2025

Eventi

Biotecnologia

Igiene alimentare

Salute

Farmaceutica

Ottica

Aurion Biotech Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025

Fonte

Aurion Biotech, Inc.

Emittente

1.00

0

10/02/2025

Biotecnologia

Farmaceutica

Ottica

Salute

Mercato del lavoro

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

Fonte

Aurion Biotech, Inc.

Emittente

1.00

0

18/12/2024

Industria

Biotecnologia

Salute

Farmaceutica

Ottica

Medicina - Varie

Aurion Biotech Announces Positive Topline Data for Phase 1/2 Clinical Trial of AURN001, an Allogeneic Cell Therapy Product Candidate for the Treatment of Corneal Edema Secondary to Corneal Endothelial Dysfunction

Fonte

Aurion Biotech, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0